Cargando…
A New In Vivo Screening Paradigm to Accelerate Antimalarial Drug Discovery
The emergence of resistance to available antimalarials requires the urgent development of new medicines. The recent disclosure of several thousand compounds active in vitro against the erythrocyte stage of Plasmodium falciparum has been a major breakthrough, though converting these hits into new med...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3692522/ https://www.ncbi.nlm.nih.gov/pubmed/23825598 http://dx.doi.org/10.1371/journal.pone.0066967 |
_version_ | 1782274632855846912 |
---|---|
author | Jiménez-Díaz, María Belén Viera, Sara Ibáñez, Javier Mulet, Teresa Magán-Marchal, Noemí Garuti, Helen Gómez, Vanessa Cortés-Gil, Lorena Martínez, Antonio Ferrer, Santiago Fraile, María Teresa Calderón, Félix Fernández, Esther Shultz, Leonard D. Leroy, Didier Wilson, David M. García-Bustos, José Francisco Gamo, Francisco Javier Angulo-Barturen, Iñigo |
author_facet | Jiménez-Díaz, María Belén Viera, Sara Ibáñez, Javier Mulet, Teresa Magán-Marchal, Noemí Garuti, Helen Gómez, Vanessa Cortés-Gil, Lorena Martínez, Antonio Ferrer, Santiago Fraile, María Teresa Calderón, Félix Fernández, Esther Shultz, Leonard D. Leroy, Didier Wilson, David M. García-Bustos, José Francisco Gamo, Francisco Javier Angulo-Barturen, Iñigo |
author_sort | Jiménez-Díaz, María Belén |
collection | PubMed |
description | The emergence of resistance to available antimalarials requires the urgent development of new medicines. The recent disclosure of several thousand compounds active in vitro against the erythrocyte stage of Plasmodium falciparum has been a major breakthrough, though converting these hits into new medicines challenges current strategies. A new in vivo screening concept was evaluated as a strategy to increase the speed and efficiency of drug discovery projects in malaria. The new in vivo screening concept was developed based on human disease parameters, i.e. parasitemia in the peripheral blood of patients on hospital admission and parasite reduction ratio (PRR), which were allometrically down-scaled into P. berghei-infected mice. Mice with an initial parasitemia (P(0)) of 1.5% were treated orally for two consecutive days and parasitemia measured 24 h after the second dose. The assay was optimized for detection of compounds able to stop parasite replication (PRR = 1) or induce parasite clearance (PRR >1) with statistical power >99% using only two mice per experimental group. In the P. berghei in vivo screening assay, the PRR of a set of eleven antimalarials with different mechanisms of action correlated with human-equivalent data. Subsequently, 590 compounds from the Tres Cantos Antimalarial Set with activity in vitro against P. falciparum were tested at 50 mg/kg (orally) in an assay format that allowed the evaluation of hundreds of compounds per month. The rate of compounds with detectable efficacy was 11.2% and about one third of active compounds showed in vivo efficacy comparable with the most potent antimalarials used clinically. High-throughput, high-content in vivo screening could rapidly select new compounds, dramatically speeding up the discovery of new antimalarial medicines. A global multilateral collaborative project aimed at screening the significant chemical diversity within the antimalarial in vitro hits described in the literature is a feasible task. |
format | Online Article Text |
id | pubmed-3692522 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-36925222013-07-02 A New In Vivo Screening Paradigm to Accelerate Antimalarial Drug Discovery Jiménez-Díaz, María Belén Viera, Sara Ibáñez, Javier Mulet, Teresa Magán-Marchal, Noemí Garuti, Helen Gómez, Vanessa Cortés-Gil, Lorena Martínez, Antonio Ferrer, Santiago Fraile, María Teresa Calderón, Félix Fernández, Esther Shultz, Leonard D. Leroy, Didier Wilson, David M. García-Bustos, José Francisco Gamo, Francisco Javier Angulo-Barturen, Iñigo PLoS One Research Article The emergence of resistance to available antimalarials requires the urgent development of new medicines. The recent disclosure of several thousand compounds active in vitro against the erythrocyte stage of Plasmodium falciparum has been a major breakthrough, though converting these hits into new medicines challenges current strategies. A new in vivo screening concept was evaluated as a strategy to increase the speed and efficiency of drug discovery projects in malaria. The new in vivo screening concept was developed based on human disease parameters, i.e. parasitemia in the peripheral blood of patients on hospital admission and parasite reduction ratio (PRR), which were allometrically down-scaled into P. berghei-infected mice. Mice with an initial parasitemia (P(0)) of 1.5% were treated orally for two consecutive days and parasitemia measured 24 h after the second dose. The assay was optimized for detection of compounds able to stop parasite replication (PRR = 1) or induce parasite clearance (PRR >1) with statistical power >99% using only two mice per experimental group. In the P. berghei in vivo screening assay, the PRR of a set of eleven antimalarials with different mechanisms of action correlated with human-equivalent data. Subsequently, 590 compounds from the Tres Cantos Antimalarial Set with activity in vitro against P. falciparum were tested at 50 mg/kg (orally) in an assay format that allowed the evaluation of hundreds of compounds per month. The rate of compounds with detectable efficacy was 11.2% and about one third of active compounds showed in vivo efficacy comparable with the most potent antimalarials used clinically. High-throughput, high-content in vivo screening could rapidly select new compounds, dramatically speeding up the discovery of new antimalarial medicines. A global multilateral collaborative project aimed at screening the significant chemical diversity within the antimalarial in vitro hits described in the literature is a feasible task. Public Library of Science 2013-06-25 /pmc/articles/PMC3692522/ /pubmed/23825598 http://dx.doi.org/10.1371/journal.pone.0066967 Text en © 2013 Jiménez-Díaz et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Jiménez-Díaz, María Belén Viera, Sara Ibáñez, Javier Mulet, Teresa Magán-Marchal, Noemí Garuti, Helen Gómez, Vanessa Cortés-Gil, Lorena Martínez, Antonio Ferrer, Santiago Fraile, María Teresa Calderón, Félix Fernández, Esther Shultz, Leonard D. Leroy, Didier Wilson, David M. García-Bustos, José Francisco Gamo, Francisco Javier Angulo-Barturen, Iñigo A New In Vivo Screening Paradigm to Accelerate Antimalarial Drug Discovery |
title | A New In Vivo Screening Paradigm to Accelerate Antimalarial Drug Discovery |
title_full | A New In Vivo Screening Paradigm to Accelerate Antimalarial Drug Discovery |
title_fullStr | A New In Vivo Screening Paradigm to Accelerate Antimalarial Drug Discovery |
title_full_unstemmed | A New In Vivo Screening Paradigm to Accelerate Antimalarial Drug Discovery |
title_short | A New In Vivo Screening Paradigm to Accelerate Antimalarial Drug Discovery |
title_sort | new in vivo screening paradigm to accelerate antimalarial drug discovery |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3692522/ https://www.ncbi.nlm.nih.gov/pubmed/23825598 http://dx.doi.org/10.1371/journal.pone.0066967 |
work_keys_str_mv | AT jimenezdiazmariabelen anewinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery AT vierasara anewinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery AT ibanezjavier anewinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery AT muletteresa anewinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery AT maganmarchalnoemi anewinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery AT garutihelen anewinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery AT gomezvanessa anewinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery AT cortesgillorena anewinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery AT martinezantonio anewinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery AT ferrersantiago anewinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery AT frailemariateresa anewinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery AT calderonfelix anewinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery AT fernandezesther anewinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery AT shultzleonardd anewinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery AT leroydidier anewinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery AT wilsondavidm anewinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery AT garciabustosjosefrancisco anewinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery AT gamofranciscojavier anewinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery AT angulobartureninigo anewinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery AT jimenezdiazmariabelen newinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery AT vierasara newinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery AT ibanezjavier newinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery AT muletteresa newinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery AT maganmarchalnoemi newinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery AT garutihelen newinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery AT gomezvanessa newinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery AT cortesgillorena newinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery AT martinezantonio newinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery AT ferrersantiago newinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery AT frailemariateresa newinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery AT calderonfelix newinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery AT fernandezesther newinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery AT shultzleonardd newinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery AT leroydidier newinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery AT wilsondavidm newinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery AT garciabustosjosefrancisco newinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery AT gamofranciscojavier newinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery AT angulobartureninigo newinvivoscreeningparadigmtoaccelerateantimalarialdrugdiscovery |